Kazia Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Kazia Therapeutics kazanç ve gelirinin sırasıyla yıllık 44.6% ve 69.5% oranında artması tahmin edilirken, EPS'nin yıllık 52.7% oranında büyümesi bekleniyor.

Anahtar bilgiler

44.6%

Kazanç büyüme oranı

52.75%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.2%
Gelir büyüme oranı	69.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	13 Aug 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Jul 06

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

The ADRs of Australian biotech Kazia Therapeutics (NASDAQ:KZIA) gained 8% Wednesday after the company announced that the U.S. Food and Drug Administration (FDA) granted the Rare Pediatric Disease Designation for an experimental therapy targeted at a form of childhood cancer. Paxalisib a brain-penetrant inhibitor received the designation as a treatment for atypical rhabdoid / teratoid tumors (AT/RT), a rare and highly aggressive childhood brain cancer, Kazia (KZIA) said in a press release. In awarding the RPD tag, the federal agency picks drug candidates targeted at serious and life-threatening diseases affecting less than 200K individuals in the U.S. with a primary impact on children aged 18 years or younger. If a drug with a rare pediatric disease designation wins FDA approval, the sponsor of its marketing application is entitled to receive a Priority Review Voucher (PRV) from the regulator. The PRVs valued at more than $100M historically, can be redeemed to receive a priority review for any subsequent marketing application, or it can be sold. In June, Kazia (KZIA) announced that the FDA awarded orphan drug designation for Paxalisib for the same condition.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:KZIA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (AUD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
6/30/2029	13	-40	-28	-57	3
6/30/2028	0	-38	-28	-34	3
6/30/2027	0	-31	-28	-22	3
6/30/2026	0	-26	-27	-25	3
12/31/2025	2	-23	-14	-14	N/A
9/30/2025	2	-22	-14	-14	N/A
6/30/2025	2	-21	-13	-13	N/A
3/31/2025	2	-25	-12	-12	N/A
12/31/2024	3	-28	-12	-12	N/A
9/30/2024	2	-28	-11	-11	N/A
6/30/2024	2	-27	-10	-10	N/A
3/31/2024	1	-21	-11	-11	N/A
12/31/2023	0	-16	-13	-13	N/A
9/30/2023	0	-18	-14	-14	N/A
6/30/2023	0	-20	-15	-15	N/A
3/31/2023	0	-23	-18	-18	N/A
12/31/2022	N/A	-25	-20	-20	N/A
9/30/2022	0	-25	-21	-21	N/A
6/30/2022	0	-25	-23	-23	N/A
3/31/2022	8	-20	-15	-15	N/A
12/31/2021	15	-15	-8	-8	N/A
9/30/2021	15	-12	-9	-9	N/A
6/30/2021	15	-8	-9	-9	N/A
3/31/2021	8	-11	-14	-14	N/A
12/31/2020	0	-13	-18	-18	N/A
9/30/2020	1	-13	-14	-14	N/A
6/30/2020	1	-12	-9	-9	N/A
3/31/2020	1	-11	-7	-7	N/A
12/31/2019	1	-10	-5	-5	N/A
9/30/2019	1	-10	N/A	-6	N/A
6/30/2019	1	-10	N/A	-7	N/A
3/31/2019	2	-11	N/A	-6	N/A
12/31/2018	2	-12	N/A	-5	N/A
9/30/2018	3	-9	N/A	-7	N/A
6/30/2018	3	-6	N/A	-9	N/A
3/31/2018	4	-6	N/A	-10	N/A
12/31/2017	6	-6	N/A	-12	N/A
9/30/2017	7	-8	N/A	-12	N/A
6/30/2017	9	-11	N/A	-11	N/A
3/31/2017	7	-12	N/A	-12	N/A
12/31/2016	5	-12	N/A	-12	N/A
9/30/2016	4	-12	N/A	-12	N/A
6/30/2016	3	-12	N/A	-12	N/A
3/31/2016	3	-10	N/A	-12	N/A
12/31/2015	3	-9	N/A	-12	N/A
9/30/2015	2	-8	N/A	-9	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: KZIA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: KZIA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: KZIA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: KZIA şirketinin gelirinin (yıllık 69.5% ) US pazarından (yıllık 12.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: KZIA şirketinin gelirinin (yıllık 69.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: KZIA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/20 00:33
Gün Sonu Hisse Fiyatı	2026/08/20 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/06/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Kazia Therapeutics Limited 7 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kambiz Yazdi	BTIG
John Newman	Canaccord Genuity
Soo Romanoff	Edison Investment Research

Kazia Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus EPS estimates upgraded to AU$0.016 loss

Recent updates

Kazia Therapeutics Files Provisional Patent Application For Novel Therapeutic Strategy To Prevent Metastatic Recurrence In Triple-Negative Breast Cancer

New major risk - Revenue and earnings growth

Kazia Therapeutics Limited Announces Appointment of James Levine to Chief Financial Officer, Effective June 1, 2026

Consensus EPS estimates upgraded to AU$0.016 loss

Kazia Therapeutics Expands Ongoing Phase 1B Trial of Paxalisib in Advanced Breast Cancer

Kazia Therapeutics Limited Appoints Dr. Sudha Rao as Chief Scientific Officer

Kazia Therapeutics Limited Expands Oncology Platform with First-In-Class SETDB1 Inhibitor Drug Development Platform

First half 2026 earnings released: AU$4.02 loss per share (vs AU$12.29 loss in 1H 2025)

New major risk - Negative shareholders equity

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $100 million.

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1B Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations Including TNBC and HER2+

Kazia Therapeutics Limited announced that it expects to receive $50.000896 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Velan Capital Partners LP, Revach Capital Management LLC

Kazia Therapeutics Limited Achieves Initial iCR (Immune- Complete Response) in Metastatic TNBC and Delivers Fourth Quarter Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy

Kazia Therapeutics Limited announced delayed 20-F filing

Kazia Therapeutics Limited Plans to Request Type C Meeting with U.S. Food & Drug Administration to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA Initiative Project FrontRunner

Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic Tnbc Patient Treatment with Paxalisib-Immunotherapy Regimen

Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage Iv Her2-Positive Breast Cancer with Paxalisib Monotherapy

Kazia Therapeutics Limited announced that it expects to receive $2.049992 million in funding

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $1.906196 million.

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen Achieves >50% Reduction in Circulating Tumor Cells in Phase 1B Trial

First half 2025 earnings released: AU$12.29 loss per share (vs AU$18.40 loss in 1H 2024)

Kazia Therapeutics Announces Transformative Preclinical Data Demonstrating Paxalisib's Potential to Overcome Immunotherapy Resistance in Triple-Negative Breast Cancer

Kazia Therapeutics Limited Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer

New minor risk - Financial data availability

High number of new and inexperienced directors

Kazia Therapeutics Limited Announces the Launch of A Groundbreaking Trial with Paxalisib in Combination with Immunotherapy in Women with Advanced Breast Cancer

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.999922 million.

Kazia Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $2 million.

Kazia Therapeutics Limited Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA

Kazia Therapeutics Limited Announces to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium

Kazia Therapeutics Limited Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme

Kazia Therapeutics Limited announced delayed 20-F filing

New minor risk - Financial data availability

Kazia Therapeutics Announces Presentation of Evt801 Clinical Data At 15 Biennial Ovarian Cancer Research Symposium

New major risk - Market cap size

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $10 million.

Kazia Therapeutics Limited Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients

Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP

New major risk - Share price stability

New major risk - Financial position

New minor risk - Financial data availability

Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Kazia Therapeutics Limited Announces Appointment of Board Members

Kazia Therapeutics Limited Announces Executive Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of $1.981756 million.

Kazia Therapeutics Announces Receipt of Nasdaq Minimum Bid Notification

High number of new and inexperienced directors

Kazia Therapeutics Provides Preliminary Update from Ongoing Phase 2 Study of Paxalisib in Primary Cns Lymphoma

Kazia Therapeutics Limited Announces Clinical Data At ESMO 2023 from Ongoing Phase 1 ESMO Study

Kazia Therapeutics Limited Announces Acceptance of Late-Breaking Abstracts and Oral Presentation of Pnoc022 Clinical Data At 2023 Society for Neuro-Oncology Annual Meeting

Kazia Therapeutics Limited, Annual General Meeting, Nov 08, 2023

Kazia Therapeutics Limited Announces Change to Board of Directors

Kazia Therapeutics Limited Appoints John Friend as Managing Director

Kazia Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.5 million.

Kazia Therapeutics Limited Receives Fast Track Designation from FDA for Treatment of Solid Tumor Brain Metastases Harboring PI3K Pathway Mutations in Combination with Radiation Therapy

Kazia Therapeutics Limited Announces Phase II Clinical Study to Investigate Paxalisib in Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma

Kazia Therapeutics Limited Appoints Ms. Ebru Davidson to its Board

Kazia gains on FDA’s rare pediatric disease designation for childhood cancer therapy

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları